Secondary prevention in non-valvular atrial fibrillation patients: a practical approach with edoxaban

References

• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983–8.
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69(6):546–54.
   PubMed Web of Science ®Google Scholar
• Christiansen CB, Gerds TA, Olesen JB, et al. Atrial fibrillation and risk of stroke: a nationwide cohort study. Europace 2016. [Epub ahead of print].
   Web of Science ®Google Scholar
• van den Ham HA, Klungel OH, Singer DE, et al. Comparative performance of ATRIA, CHADS2, and CHA2DS2-VASc risk scores predicting stroke in patients with atrial fibrillation: results from a national primary care database. J Am Coll Cardiol 2015;66(17):1851–9.
   PubMed Web of Science ®Google Scholar
• Masjuán J, Álvarez-Sabín J, Blanco M, et al. Current management of antithrombotic treatment in patients with non valvular atrial fibrillation and prior history of stroke or transient ischemic attack. Rev Neurol 2014;59(1):25–36.
   PubMed Web of Science ®Google Scholar
• Hayden DT, Hannon N, Callaly E, et al. Rates and determinants of 5-year outcomes after atrial fibrillation-related stroke: a population study. Stroke 2015;46(12):3488–93.
   PubMed Web of Science ®Google Scholar
• Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian Stroke Registry. Eur Heart J 2004;25(19):1734–40.
   PubMed Web of Science ®Google Scholar
• Sussman M, Menzin J, Lin I, et al. Impact of atrial fibrillation on stroke-related healthcare costs. J Am Heart Assoc 2013;2(6):e000479.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European society of cardiology (ESC). Eur Heart J 2010;31(19):2369–429.
   PubMed Web of Science ®Google Scholar
• Kim WJ, Park JM, Kang K, et al. Adherence to guidelines for antithrombotic therapy in patients with atrial fibrillation according to CHADS2 score before and after stroke: a multicenter observational study from Korea. J Clin Neurol 2016;12(1):34–41.
   PubMed Web of Science ®Google Scholar
• Haeusler KG, Gerth A, Limbourg T, et al. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. BMC Neurol 2015;15:129.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol 2016;67(25):2913–23.
   PubMed Web of Science ®Google Scholar
• McGrath ER, Kapral MK, Fang J, et al. Investigators of the Ontario Stroke Registry. Antithrombotic therapy after acute ischemic stroke in patients with atrial fibrillation. Stroke 2014;45(12):3637–42.
   PubMed Web of Science ®Google Scholar
• Tanislav C, Milde S, Schwartzkopff S, et al. Secondary stroke prevention in atrial fibrillation: a challenge in the clinical practice. BMC Neurol 2014;14:195.
   PubMed Web of Science ®Google Scholar
• Bangalore S, Schwamm L, Smith EE, et al. Get with the guidelines-stroke steering committee and investigators. Secondary prevention after ischemic stroke or transient ischemic attack. Am J Med 2014;127(8):728–38.
   PubMed Web of Science ®Google Scholar
• Arnao V, Agnelli G, Paciaroni M. Direct oral anticoagulants in the secondary prevention of stroke and transient ischemic attack in patients with atrial fibrillation. Intern Emerg Med 2015;10(5):555–60.
   PubMed Web of Science ®Google Scholar
• Kodani E, Atarashi H, Inoue H, et al. J-RHYTHM registry investigators. Secondary prevention of stroke with warfarin in patients with nonvalvular atrial fibrillation: subanalysis of the J-RHYTHM registry. J Stroke Cerebrovasc Dis 2016;25(3):585–99.
   PubMed Web of Science ®Google Scholar
• Esenwa C, Gutierrez J. Secondary stroke prevention: challenges and solutions. Vasc Health Risk Manag 2015;11:437–50.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C. Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. Expert Rev Cardiovasc Ther 2015;13(7):811–24.
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderón A, Escobar C, et al. Primary care group in the clinical cardiology section of the Spanish society of cardiology. Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl Ed) 2012;65(1):47–53.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383(9921):955–62.
   PubMed Web of Science ®Google Scholar
• Sardar P, Chatterjee S, Wu WC, et al. New oral anticoagulants are not superior to warfarin in secondary prevention of stroke or transient ischemic attacks, but lower the risk of intracranial bleeding: insights from a meta-analysis and indirect treatment comparisons. PLoS One 2013;8(10):e77694.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Mavridis D, et al. Novel Oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Stroke 2016;47:A37.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Lixiana®, “Summary of Product Characteristics”; 2015. Available at: http://www.ema .europa.eu/docs/en_GB/document_library/EPAR_-_Product_ Information/human/002629/WC500189045.pdf [Updated 18 Nov 2015].
   Google Scholar
• Food and Drug Administration. Savaysa® (edoxaban tosylate) tablets prescribing information. 2015. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/ 206316s002lbl.pdf
   Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. ENGAGE AF-TIMI 48 investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093–104.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost 2010;104(3):633–41.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 2015;385(9984):2288–95.
   PubMed Web of Science ®Google Scholar
• Barrios V, Escobar C, Prieto L, et al. Anticoagulation control in patients with nonvalvular atrial fibrillation attended at primary care centers in Spain: the PAULA study. Rev Esp Cardiol (Engl Ed) 2015;68(9):769–76.
   PubMed Web of Science ®Google Scholar
• Pokorney SD, Simon DN, Thomas L, et al. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: results from ORBIT-AF registry. Am Heart J 2015;170(1):141–8.
   PubMed Web of Science ®Google Scholar
• Anguita Sánchez M, Bertomeu Martínez V, Cequier Fillat Á. CALIFA study researchers. Quality of vitamin K antagonist anticoagulation in Spain: prevalence of poor control and associated factors. Rev Esp Cardiol (Engl Ed) 2015;68(9):761–8.
   PubMed Web of Science ®Google Scholar
• Rost NS, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban vs. warfarin in high-risk patients: the ENGAGE AF-TIMI 48 trial. Int J Stroke 2014;9(Suppl. 3):WSC–38.
   Google Scholar
• Giugliano RP, Ruff CT, Rost NS, et al. ENGAGE AF-TIMI 48 investigators. Cerebrovascular events in 21105 patients with atrial fibrillation randomized to edoxaban versus warfarin: effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48. Stroke 2014;45(8):2372–8.
   PubMed Web of Science ®Google Scholar
• Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: ENGAGE AF-TIMI 48. Circulation 2014;130:A16612.
   Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011;123(21):2363–72.
   PubMed Web of Science ®Google Scholar
• Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban versus warfarin in patients at increased risk of falling – a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Circulation 2015;132:A11748.
   Web of Science ®Google Scholar
• Magnani G, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban compared with warfarin in patients with atrial fibrillation and heart failure: insights from engage-AF TIMI 48. Circulation 2014;130:A12680.
   Web of Science ®Google Scholar
• O'Donoghue ML, Ruff CT, Giugliano RP, et al. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation. Eur Heart J 2015;36(23):1470–7.
   PubMed Web of Science ®Google Scholar
• Xu H, Ruff CT, Giugliano RP, et al. Concomitant use of antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Circulation 2014;130:A19119.
   Web of Science ®Google Scholar
• Steffel J, Giugliano RP, Braunwald E, et al. Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 2015;36(33):2239–45.
   PubMed Web of Science ®Google Scholar
• Blann AD, Banerjee A, Lane DA, et al. Net clinical benefit of edoxaban versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Int J Cardiol 2015;201:693–8.
   PubMed Web of Science ®Google Scholar
• Di Minno A, Spadarella G, Tufano A, et al. Ensuring medication adherence with direct oral anticoagulant drugs: lessons from adherence with vitamin K antagonists (VKAs). Thromb Res 2014;133(5):699–704.
   PubMed Web of Science ®Google Scholar
• Beyer-Westendorf J, Ehlken B, Evers T. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. Europace 2016;18(8):1150–7.
   PubMed Web of Science ®Google Scholar
• Laliberté F, Nelson WW, Lefebvre P, et al. Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 2012;29(8):675–90.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Truitt KE. Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa. Clin Pharmacokinet 2016;55(6):641–55.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Edoxaban: a review in nonvalvular atrial fibrillation. Am J Cardiovasc Drugs 2015;15(5):351–61.
   PubMed Web of Science ®Google Scholar
• Parasrampuria DA, Kanamaru T, Connor A, et al. Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule. J Clin Pharmacol 2015;55(11):1286–92.
   PubMed Web of Science ®Google Scholar
• Jönsson S, Simonsson US, Miller R, et al. Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study. J Clin Pharmacol 2015;55(11):1268–79.
   PubMed Web of Science ®Google Scholar
• Mendell J, Chen S, He L, et al. The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Invest 2015;35(7):447–53.
   PubMed Web of Science ®Google Scholar
• Lip GY, Agnelli G. Edoxaban: a focused review of its clinical pharmacology. Eur Heart J 2014;35(28):1844–55.
   PubMed Web of Science ®Google Scholar
• Plitt A, Giugliano RP. Edoxaban: review of pharmacology and key phase I to III clinical trials. J Cardiovasc Pharmacol Ther 2014;19(5):409–16.
   PubMed Web of Science ®Google Scholar
• Mikkaichi T, Yoshigae Y, Masumoto H, et al. Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition. Drug Metab Dispos 2014;42(4):520–8.
   PubMed Web of Science ®Google Scholar
• Peacock WF, Levy PD, Gonzalez MG, et al. Target-specific oral anticoagulants in the emergency department. J Emerg Med 2016;50(2):246–57.
   PubMed Web of Science ®Google Scholar
• Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis 2015;39(3):288–94.
   PubMed Web of Science ®Google Scholar
• Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol 2015;143(2):241–7.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. ESC Committee for Practice Guidelines (CPG) 2012, focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719–47.
   PubMed Web of Science ®Google Scholar
• Frank Peacock W, Gearhart MM, Mills RM. Emergency management of bleeding associated with old and new oral anticoagulants. Clin Cardiol 2012;35(12):730–7.
   PubMed Web of Science ®Google Scholar
• Sanchez M, Escolar G, Reverter JC. Bleeding in patients on anticoagulant therapy: the real utility of antidotes and how to manage bleeding in patients on new-generation oral anticoagulants. Emergencias 2013;25:482–90.
   Web of Science ®Google Scholar
• Frontera JA, Lewin Iii JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care. 2016;24(1):6–46.
   PubMed Web of Science ®Google Scholar
• Das A, Liu D. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol 2015;4:25.
   PubMedGoogle Scholar
• Herzog E, Kaspereit F, Krege W, et al. Effective reversal of edoxaban-associated bleeding with four-factor prothrombin complex concentrate in a rabbit model of acute hemorrhage. Anesthesiology 2015;122(2):387–98.
   PubMed Web of Science ®Google Scholar
• Zahir H, Brown KS, Vandell AG, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation 2015;131(1):82–90.
   PubMed Web of Science ®Google Scholar
• Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 2014;371(22):2141–2.
   PubMed Web of Science ®Google Scholar
• Crowther M, Gold AM, Lu G, et al. Andexanet alfa, a universal antidote for reversal of anticoagulation of factor Xa inhibitors in healthy human volunteers. Stroke 2016;47:A212.
   Web of Science ®Google Scholar
• Lansberg MG, O'Donnell MJ, Khatri P, et al. American college of chest physicians. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e601S–36S.
   PubMed Web of Science ®Google Scholar
• Fuentes B, Gállego J, Gil-Nuñez A, et al. Committee of the cerebrovascular diseases study group of the Spanish neurological. Guidelines for the preventive treatment of ischaemic stroke and TIA (II). Recommendations according to aetiological sub-type. Neurologia 2014;29(3):168–83.
   PubMed Web of Science ®Google Scholar
• Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45(7):2160–236.
   PubMed Web of Science ®Google Scholar
• Lekuona I, Anguita M, Zamorano JL, et al. Is edoxaban cost-effective for non-valvular atrial fibrillation patients treated with vitamin K antagonists in spain? Value health. 2015;18(7):A392.
   PubMed Web of Science ®Google Scholar
• Krejczy M, Harenberg J, Wehling M, et al. Cost-effectiveness of anticoagulation in patients with nonvalvular atrial fibrillation with edoxaban compared to warfarin in Germany. Biomed Res Int 2015;2015:876923.
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, et al. Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. J Thromb Thrombolysis 2015;39(2):149–54.
   PubMed Web of Science ®Google Scholar
• Coutts SB, Wein TH, Lindsay MP, et al. Canadian stroke best practice recommendations: secondary prevention of stroke guidelines, update 2014. Int J Stroke 2015;10(3):282–91.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Falocci N, et al. Early recurrence and cerebral bleeding in patients with acute ischemic stroke and atrial fibrillation: effect of anticoagulation and its timing: the RAF study. Stroke 2015;46(8):2175–82.
   PubMed Web of Science ®Google Scholar
• Lin YP, Tan TY. Do NOACs improve antithrombotic therapy in secondary stroke prevention in nonvalvular atrial fibrillation? Medicine (Baltimore). 2015;94(38):e1627.
   PubMed Web of Science ®Google Scholar
• Sauer R, Sauer EM, Bobinger T, et al. Adherence to oral anticoagulation in secondary stroke prevention–the first year of direct oral anticoagulants. J Stroke Cerebrovasc Dis 2015;24(1):78–82.
   PubMed Web of Science ®Google Scholar